A detailed history of Bradley Foster & Sargent Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Bradley Foster & Sargent Inc holds 39,381 shares of GILD stock, worth $3.3 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
39,381
Previous 38,739 1.66%
Holding current value
$3.3 Million
Previous $2.84 Million 4.79%
% of portfolio
0.05%
Previous 0.05%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$63.15 - $72.88 $40,542 - $46,788
642 Added 1.66%
39,381 $2.7 Million
Q1 2024

May 15, 2024

SELL
$71.58 - $87.29 $334,063 - $407,382
-4,667 Reduced 10.75%
38,739 $2.84 Million
Q4 2023

Feb 14, 2024

SELL
$73.27 - $83.09 $232,852 - $264,060
-3,178 Reduced 6.82%
43,406 $3.52 Million
Q2 2023

Aug 08, 2023

BUY
$76.01 - $86.7 $182,804 - $208,513
2,405 Added 5.44%
46,584 $3.59 Million
Q1 2023

May 08, 2023

BUY
$77.31 - $88.08 $14,070 - $16,030
182 Added 0.41%
44,179 $3.67 Million
Q4 2022

Feb 14, 2023

BUY
$62.32 - $89.47 $24,990 - $35,877
401 Added 0.92%
43,997 $3.78 Million
Q3 2022

Nov 14, 2022

BUY
$59.54 - $68.01 $7,859 - $8,977
132 Added 0.3%
43,596 $2.69 Million
Q2 2022

Aug 11, 2022

SELL
$57.72 - $65.01 $41,904 - $47,197
-726 Reduced 1.64%
43,464 $2.69 Million
Q1 2022

May 16, 2022

SELL
$57.92 - $72.58 $265,679 - $332,924
-4,587 Reduced 9.4%
44,190 $2.63 Million
Q4 2021

Mar 11, 2022

BUY
$64.88 - $73.64 $297,409 - $337,565
4,584 Added 10.37%
48,777 $3.54 Million
Q3 2021

Nov 10, 2021

BUY
$67.69 - $73.03 $2,369 - $2,556
35 Added 0.08%
44,193 $3.09 Million
Q2 2021

Aug 19, 2021

BUY
$63.47 - $69.35 $76,417 - $83,497
1,204 Added 2.8%
44,158 $3.04 Million
Q1 2021

Apr 26, 2021

BUY
$60.0 - $68.46 $6,660 - $7,599
111 Added 0.26%
42,954 $2.78 Million
Q4 2020

Feb 11, 2021

SELL
$56.65 - $64.55 $678,043 - $772,598
-11,969 Reduced 21.84%
42,843 $2.5 Million
Q3 2020

Oct 26, 2020

BUY
$62.1 - $78.08 $1.13 Million - $1.42 Million
18,218 Added 49.78%
54,812 $3.46 Million
Q1 2020

May 07, 2020

SELL
$62.63 - $80.22 $46,721 - $59,844
-746 Reduced 2.0%
36,594 $2.74 Million
Q4 2019

Jan 29, 2020

SELL
$61.62 - $67.78 $5,730 - $6,303
-93 Reduced 0.25%
37,340 $2.43 Million
Q3 2019

Oct 30, 2019

SELL
$62.51 - $69.0 $6,063 - $6,693
-97 Reduced 0.26%
37,433 $2.37 Million
Q2 2019

Aug 08, 2019

SELL
$61.87 - $69.38 $30,316 - $33,996
-490 Reduced 1.29%
37,530 $2.54 Million
Q1 2019

May 02, 2019

SELL
$62.53 - $70.05 $98,734 - $110,608
-1,579 Reduced 3.99%
38,020 $2.47 Million
Q4 2018

Jan 30, 2019

SELL
$60.54 - $79.0 $212,677 - $277,527
-3,513 Reduced 8.15%
39,599 $2.48 Million
Q3 2018

Oct 31, 2018

BUY
$71.28 - $78.92 $29,224 - $32,357
410 Added 0.96%
43,112 $3.33 Million
Q2 2018

Jul 31, 2018

SELL
$64.88 - $75.68 $943,095 - $1.1 Million
-14,536 Reduced 25.4%
42,702 $3.03 Million
Q1 2018

May 07, 2018

SELL
$72.84 - $88.8 $6,555 - $7,992
-90 Reduced 0.16%
57,238 $4.32 Million
Q4 2017

Feb 06, 2018

SELL
$71.15 - $83.52 $499,544 - $586,393
-7,021 Reduced 10.91%
57,328 $4.11 Million
Q3 2017

Nov 03, 2017

BUY
$72.11 - $85.47 $4.64 Million - $5.5 Million
64,349
64,349 $5.21 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $105B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Bradley Foster & Sargent Inc Portfolio

Follow Bradley Foster & Sargent Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bradley Foster & Sargent Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bradley Foster & Sargent Inc with notifications on news.